Skip to main content
SpringerLink
Log in

Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The pure antiestrogen ICI 182,780 has been shown to have antiprogestin activity in reporter gene constructs. Cell lines, naturally devoid of progesterone receptors (PR) were transfected with either the A or B forms of the human PR and a luciferase construct driven by a progesterone-response element (PRE). Because this system is an artificial one, our purpose was to determine whether these observations could be made in a human breast cancer cell line, naturally containing PR. We further evaluated the dose-response of ICI 182,780 and RU-486 (mifepristone) on PR and estrogen receptors (ER) in the presence of either progesterone, norgestrel or estradiol. These effects were measured using immunoassays for prostate-specific antigen (PSA) and human glandular kallikrein (hK2) and pS2. We found that ICI 182,780 blocked progesterone-stimulated PSA and hK2 production 100% at 10−5 M, which decreased significantly by 10−6 M. This inhibition did not occur when norgestrel was the progestin used. RU-486 showed 100% blockade for both progestins at all concentrations used. We concluded that the antiprogestin activity of ICI 182,780 exists for progesterone only. This weak antiprogestin activity may be unlikely to have significant clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antioestrogen (ICI 182780) in tamoxifenresistant breast cancer. Lancet 345: 29–30, 1995

    Google Scholar 

  2. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873, 1991

    Google Scholar 

  3. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG: Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87: 6883–6887, 1990

    Google Scholar 

  4. Gibson MK, Nemmers LA, Beckman WC, Jr, Davis VL, Curtis SW, Korach KS: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000–2010, 1991

    Google Scholar 

  5. Dauvois S, White R, Parker MG: The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106: 1377–1388, 1993

    Google Scholar 

  6. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A: 576–588, 1996

    Google Scholar 

  7. Kangas L, Nieminen AL, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R: A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109–113, 1986

    Google Scholar 

  8. Favoni RE, de Cupis A: Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends in Pharmaceutical Sciences 19: 406–415, 1998

    Google Scholar 

  9. Loser R, Seibel K, Roos W, Eppenberger U: In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen: Eur J Cancer Clin Oncol 21: 985–990, 1985

    Google Scholar 

  10. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32: 1031–1036, 1983

    Google Scholar 

  11. Toko T, Sugimoto Y, Matsuo K, Yamasaki R, Takeda S, Wierzba K, Asao T, Yamada Y: TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. Eur J Cancer 26: 397–404, 1990

    Google Scholar 

  12. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851–5858, 1991

    Google Scholar 

  13. Kraus WL, Weis KE, Katzenellenbogen BS: Inhibitory crosstalk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist-and antagonist-occupied progestin receptors. Mol Cell Biol 15: 1847–1857, 1995

    Google Scholar 

  14. Jeng MH, Langan-Fahey SM, Jordan VC: Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 132: 2622–2630, 1993

    Google Scholar 

  15. Nawaz Z, Stancel GM, Hyder SM: The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 59: 372–376, 1999

    Google Scholar 

  16. Catherino WH, Jordan VC: Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92: 39–47, 1995

    Google Scholar 

  17. Hall RE, Tilley WD, McPhaul MJ, Sutherland RL: Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. Int J Cancer 52: 778–784, 1992

    Google Scholar 

  18. Christopoulos TK, Diamandis EP: Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 64: 342–346, 1992

    Google Scholar 

  19. Yu H, Diamandis EP, Zarghami N, Grass L: Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 32: 291–300, 1994

    Google Scholar 

  20. Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP: Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross reactivity from prostate specific antigen. Clin Chem 45: 790–799, 1999

    Google Scholar 

  21. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL: Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41: 399–410, 1990

    Google Scholar 

  22. Horowitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167–1177, 1996

    Google Scholar 

  23. Lange CA, Richer JK, Shen T, Horowitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogenactivated protein kinase pathways. J Biol Chem 273: 31308–31316, 1998

    Google Scholar 

  24. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horowitz KB: Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273: 31317–31326, 1998

    Google Scholar 

  25. Weaver CA, Springer PA, Katzenellenbogen BS: Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyl transferase fusion genes transfected into MCF-7 human breast cancer cells. Mol Endocrinol 2: 936–945, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nutritional Sciences, University of Toronto, Canada

    Rachel S. Rosenberg Zand & David J.A. Jenkins

  2. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto

    Rachel S. Rosenberg Zand, Linda Grass, Angeliki Magklara & Eleftherios P. Diamandis

  3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

    Angeliki Magklara & Eleftherios P. Diamandis

Authors
  1. Rachel S. Rosenberg Zand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel S. Rosenberg Zand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda Grass
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angeliki Magklara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Angeliki Magklara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David J.A. Jenkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eleftherios P. Diamandis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eleftherios P. Diamandis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zand, R.S.R., Zand, R.S.R., Grass, L. et al. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?. Breast Cancer Res Treat 60, 1–8 (2000). https://doi.org/10.1023/A:1006334132303

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006334132303

Search

Navigation